Leerink’s Risinger on Eli Lilly downgrade: Triggered by disappointing obesity pill results

David Risinger, Leerink Partners senior research analyst, joins ‘Power Lunch’ to discuss how competitive Eli Lilly’s business is, what to expect by the end of the decade and much more.